Metoclopramide Orion (Metoclopramide Hydrochloride)

Metoclopramide acts on the chemoreceptor trigger zone and gastrointestinal motility, making it useful for several gastrointestinal and emetic conditions.

• Nausea and vomiting: reduces frequency and severity of symptoms from chemotherapy, postoperative states, and migraine.
• Gastroparesis: accelerates gastric emptying and improves related discomfort.
• Gastro‑oesophageal reflux disease: decreases reflux episodes by enhancing gastric motility.
• Migraine‑associated nausea: alleviates nausea accompanying migraine attacks.

• Metoclopramide antagonizes dopamine D2 receptors in the chemoreceptor trigger zone, diminishing the emetic signal. It also blocks peripheral D2 receptors and stimulates muscarinic receptors, leading to increased acetylcholine release in the gut wall, which promotes coordinated gastrointestinal contractions and accelerates gastric emptying.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Drowsiness: feeling unusually sleepy or fatigued.
• Fatigue: reduced energy levels during daily activities.
• Diarrhea: loose, frequent stools.
• Restlessness: an inner sense of agitation or inability to stay still.

Serious or Rare Side Effects

• Tardive dyskinesia: involuntary, repetitive movements, especially with prolonged use.
• Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and muscle rigidity.
• Severe allergic reaction: rash, swelling, or difficulty breathing.

Metoclopramide should be used with caution and under professional supervision.

• Assess renal function: adjust use in severe renal impairment.
• Monitor for extrapyramidal symptoms: especially in elderly patients.
• Avoid prolonged use: limit therapy to 12 days to reduce risk of tardive dyskinesia.
• Use caution in pregnancy: category B1, weigh benefits against potential risks.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Metoclopramide can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol): increased risk of extrapyramidal symptoms.
• CYP2D6 inhibitors (e.g., fluoxetine): elevated metoclopramide plasma concentrations.
• Monoamine oxidase inhibitors: potential for hypertensive crisis.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may diminish the pro‑kinetic effect of metoclopramide.
• Diabetes medications: possible alteration of glucose control.
• Alcohol: may enhance central nervous system depression.